OncoMatch/Clinical Trials/NCT06218628
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Is NCT06218628 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Talazoparib and pacritinib for primary myelofibrosis.
Treatment: Talazoparib · pacritinib — This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myeloproliferative Neoplasm
Acute Myeloid Leukemia
Disease stage
Required: Stage INTERMEDIATE-2, HIGH-RISK (DIPSS+70)
Excluded: Stage ACUTE MYELOID LEUKEMIA
Subject classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+70). Patients that have transformed to Acute Myeloid Leukemia defined by >20% blasts count on peripheral blood smear or bone marrow biopsy evaluation [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: jak2 inhibitor
Lab requirements
Blood counts
Patients must have normal organ function as defined in protocol.
Kidney function
Patients must have normal organ function as defined in protocol.
Liver function
Patients must have normal organ function as defined in protocol.
Cardiac function
Baseline QTc (corrected QT interval) <0.47 seconds (Bazett formula)
Patients must have normal organ function as defined in protocol. Baseline QTc (corrected QT interval) <0.47 seconds (Bazett formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fox Chase Cancer Center - Philadelphia · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify